Oric Pharmaceuticals ( (ORIC) ) has provided an announcement.
On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment to the 2022 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by 1,100,000, totaling 2,250,000 shares. This move, made without stockholder approval under Nasdaq rules, aims to attract new employees and facilitate mergers or acquisitions, aligning with the company’s strategic growth and talent acquisition objectives.
More about Oric Pharmaceuticals
Oric Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative treatments and therapies. The company is involved in creating equity-based incentive plans to attract new talent and facilitate mergers and acquisitions.
YTD Price Performance: -6.78%
Average Trading Volume: 960,098
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $568.2M
Learn more about ORIC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com